PDCD1 and colorectal carcinoma: Similar results were observed with the combination of an anti-CTLA-4 and an anti-PD1 (botensilimab + balstilimab) in third-line MSS CRC, which showed signs of efficacy but with a detrimental role of liver metastases on the efficacy of anti-PD-1 + anti-CTLA-4 38.